Sight Sciences, Inc. (NASDAQ:SGHT) CTO David Badawi Sells 5,423 Shares

Sight Sciences, Inc. (NASDAQ:SGHT) CTO David Badawi sold 5,423 shares of the firm’s stock in a transaction on Friday, January 17th. The stock was sold at an average price of $2.78, for a total value of $15,075.94. Following the completion of the transaction, the chief technology officer now owns 1,744,118 shares of the company’s stock, valued at $4,848,648.04. This trade represents a 0.31 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

David Badawi also recently made the following trade(s):

• On Wednesday, January 8th, David Badawi sold 3,829 shares of Sight Sciences stock. The shares were sold at an average price of $3.26, for a total transaction of $12,482.54.
• On Friday, January 3rd, David Badawi sold 3,111 shares of Sight Sciences stock. The shares were sold at an average price of $3.52, for a total value of $10,950.72.

Sight Sciences Stock Up 2.1 %

SGHT opened at $2.89 on Wednesday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 9.74 and a current ratio of 10.18. Sight Sciences, Inc. has a 52 week low of $2.67 and a 52 week high of $8.45. The business has a fifty day simple moving average of $3.59 and a 200-day simple moving average of $5.35.

Sight Sciences (NASDAQ:SGHT) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.01. Sight Sciences had a negative net margin of 63.30% and a negative return on equity of 47.28%. The business had revenue of $20.16 million during the quarter, compared to the consensus estimate of $20.41 million. On average, equities analysts predict that Sight Sciences, Inc. will post -1.01 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on SGHT. Needham & Company LLC reissued a “hold” rating on shares of Sight Sciences in a report on Tuesday, January 14th. Citigroup lowered their price target on Sight Sciences from $5.80 to $4.60 and set a “neutral” rating on the stock in a research report on Wednesday, December 11th. Piper Sandler restated a “neutral” rating and set a $5.50 price target (down previously from $6.00) on shares of Sight Sciences in a research report on Friday, November 8th. Morgan Stanley cut their price objective on shares of Sight Sciences from $7.00 to $5.00 and set an “equal weight” rating for the company in a report on Monday, November 11th. Finally, UBS Group began coverage on Sight Sciences in a report on Friday, December 6th. They set a “buy” rating and a $5.50 target price on the stock. Five investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, Sight Sciences presently has an average rating of “Hold” and an average target price of $4.72.

Hedge Funds Weigh In On Sight Sciences

Several large investors have recently bought and sold shares of the business. KCK LTD. acquired a new stake in shares of Sight Sciences during the 4th quarter worth about $15,925,000. Barclays PLC raised its stake in Sight Sciences by 317.4% during the 3rd quarter. Barclays PLC now owns 50,300 shares of the company’s stock worth $317,000 after acquiring an additional 38,248 shares in the last quarter. Millrace Asset Group Inc. purchased a new stake in Sight Sciences in the third quarter valued at $874,000. Geode Capital Management LLC grew its holdings in shares of Sight Sciences by 1.6% during the third quarter. Geode Capital Management LLC now owns 784,129 shares of the company’s stock worth $4,941,000 after purchasing an additional 12,709 shares during the last quarter. Finally, State Street Corp lifted its holdings in shares of Sight Sciences by 17.4% in the 3rd quarter. State Street Corp now owns 646,776 shares of the company’s stock valued at $4,075,000 after purchasing an additional 95,843 shares during the last quarter. Hedge funds and other institutional investors own 55.51% of the company’s stock.

About Sight Sciences

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.